NICE u-turn sees Akcea’s Waylivra win NHS funding
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
Read More
Tag: Familial Chylomicronaemia Syndrome
Akcea’s rare lipid disorder drug wins PIM status
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
